Markets:

Overview

News

Currencies

International

Treasuries

Pear Therapeutics, Inc. - Class A Common Stock (NQ:PEAR)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 18, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Pear Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 Next >

Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process

April 07, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

April 03, 2023

From Sight Sciences, Inc.

Via GlobeNewswire

Pear Therapeutics Announces Process Exploring Strategic Alternatives

March 17, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Conference

February 27, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 02, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

January 26, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

January 18, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in Citi’s BioTech C-Suite Virtual Fireside Chat Series

January 17, 2023

From Pear Therapeutics, Inc.

Via Business Wire

California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program

January 12, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics and COEUS Healthcare Partner to Combat the Addiction Crisis With Prescription Digital Therapeutics

January 10, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics and Spero Health to Expand Access to Prescription Digital Therapeutics for People in Recovery Across Multiple Locations and States

January 04, 2023

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP

December 15, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference

November 21, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Reports Third Quarter 2022 Results

November 14, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in the BTIG Digital Health Forum

November 10, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

November 07, 2022

From Pear Therapeutics, Inc.

Via Business Wire

State of Wisconsin to Provide Access to Prescription Digital Therapeutics to Help Local Communities Fight Against Addiction Crisis

November 03, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference

November 01, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Issue Third Quarter 2022 Financial Results on Monday, November 14, 2022

October 31, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

October 24, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in LifeSci Partners HealthTech Symposium

September 13, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 07, 2022

From Pear Therapeutics, Inc.

Via Business Wire

South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders

September 01, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

August 31, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Reports Second Quarter 2022 Results

August 11, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

August 10, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics and SelectHealth Announce Coverage to Provide Access to FDA-Authorized Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

August 08, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics and Cove Behavioral Health to Provide Patients Access to Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

August 03, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to be Added to Russell US Index Series

August 02, 2022

From Pear Therapeutics, Inc.

Via Business Wire

Pear Therapeutics to Issue Second Quarter 2022 Financial Results on Thursday, August 11, 2022

July 28, 2022

From Pear Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.